logo
logo

Alzheimer's Drug Discovery Foundation Announces Major Funding Commitment to Validate an Amyloid Blood Test for Non-Invasive Early Detection of Alzheimer's Disease

Sep 23, 2020•almost 5 years ago
New York

Description

The Alzheimer's Drug Discovery Foundation (ADDF) announced today that it has awarded more than $2.2 million to C2N Diagnostics to accelerate clinical validation and accreditation of its beta-amyloid blood test for early detection of Alzheimer's disease pathology. The ADDF has been a long-time supporter of research into Alzheimer's biomarkers, including this amyloid blood test, providing $2.8 million in funding to C2N over the last decade.

Company Information

Company

The Alzheimer's Drug Discovery Foundation (Addf)

Location

New York, New York, United States

About

The Alzheimer's Drug Discovery Foundation is the only public charity solely focused on funding the development of drugs for Alzheimer's disease, employing a venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, the ADDF has awarded more than $150 million to fund over 626 Alzheimer's drug discovery programs and clinical trials in 19 countries. To learn more, please visit: https://www.alzdiscovery.org/.

Related People